Fremanezumab
Acute Mountain Sickness
Insel Gruppe AG, University Hospital Bernmonoclonal_antibodyPhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the Acute Mountain Sickness cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
LACTULOSE New York Presbyterian Brooklyn Methodist Hospital | N/A | D |
Polyethylene Glycol 3350 New York Presbyterian Brooklyn Methodist Hospital | N/A | D |
Same molecule, other indications
Fremanezumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →